Background and Aims: Multiple sclerosis (MS) is defined by the presence of inflammatory demyelinating plaques in the central nervous system (CNS). It has been indicated that human herpes virus 6 (HHV-6) may play role in pathogenesis of MS. The aim of this study was to determine the presence of HHV-6 DNA and anti HHV-6 IgG in MS patients and controls. Materials and Methods: Blood samples from 59 patients with MS and 59 healthy controls were collected. DNA extraction and real-time PCR based on (Syber Green) were done in the peripheral blood mononuclear cells (PBMCs) and in plasma specimens. Anti-HHV-6 IgG was measured by ELISA technique. Demographic and clinical data were collected and entered in SPSS 16 and analyzed. Results: HHV-6 DNA was found in the plasma sample of 1 (1.7%) of 59 MS patients. There was no HHV-6 DNA in PBMCs of the MS patients and controls and in plasma of control group. Anti-HHV-6 IgG antibody was present in 84.7% of MS patients and 82.1% of control group. Conclusion: There was no significant relation based on presence of HHV-6 DNA and antibody between MS patients and controls in north of Iran.
Introduction
. HHV-6 belongs to the Roseolavirus genus of the Subfamily β-herpesvirus and causes Exantem Subitum disease or (Roseola) a benign febrile illness with skin rash (5) . It is classified to variants A and B both can enter the CNS (6, 7) . In recent years, HHV-6 has been suggested to be a possible causative agent for MS. Several studies have examined anti HHV-6-specific antibody responses, HHV-6 DNA, or HHV-6 presence in the CNS tissue in both MS patients and controls groups (8) (9) (10) (11) (12) . Although the results reported don't indicate relation HHV-6 and MS disease clearly. The goal of this work was to clarify the incidence of HHV-6 infection in MS patients and healthy control to deter mine association between the presence of HHV-6 in MS patients as compared with the control group.
Methods
Fifty nine MS patients and 59 healthy individuals as control group from Golestan province in north of Iran were selected in 2014. Control group did not have any symptoms of MS and were matched for age, gender, and socioeconomic status. Subsequently demographic and clinical data were recorded. 5 mL of whole blood with EDTA were obtained from MS patients (RRMS samples were collected in remission phase) and control group and separated its plasma and PBMC for DNA extraction and antibody detection. All samples were frozen in -80°C until further examinations. DNA Extraction. DNA extraction of plasma samples was performed according to Özaslan et al. (13) which is summarized below. HHV-6 DNA was extracted from 200 μl plasma, with addition of 500μl K buffer (20m M Tris, 10 mM EDTA, 0.2%SDS, 150 mM NaCl, 20μl/ml Proteinase K 25mg/ml) and incubated at 37°C for 2h. The microtubes were centrifuged at 11,000 rpm at 4°C for 6 min, then DNA was extracted by phenol-chloroform-isoamyl alcohol (25:24:1) allowed by ethanol precipitation. Then, DNA was dissolved in 30μl sterile distilled water stored at −20°C until use for PCR. DNA extraction of PBMC samples was performed according to Shahbazi et al.(14) which is summarized below. The protocol applied for DNA extraction of the PBMC samples was based on the lyses of the erythrocytes with R buffer (ammonium carbonate, potassium hydrogen carbonate, EDTA 0.5 M). Then 700 µl salt EDTA, 25μl proteinase K (25 mg/ml) and 30 µl SDS 10% were added to the pellet, which was incubated for 1h at 65°C. After incubation, mixture of phenol-chloroform-isoamyl alcohol was added to samples, which were then centrifuged. To precipitate the DNA, with adding isopropanol and sodium acetate to the supernatant, DNA was extracted after centrifugation. All samples were dissolved in 100µl sterile distill water and stored at −20 °C for future analysis. Genomic DNA PCR (Internal control). PCR test (Internal control) was done for controlling DNA extraction in both samples (plasma and PBMC) for a sequence 250 bp of the human GAPDH gene, (Genetbio, Korea pcr kit, Eppendorf thermocycler). Reverse primer Human GAPDH: GAAGGTGAAGGTCGGAGTC, Forward primer Human GAPDH: GAAGATGGTGATGGGATTTC (15) . Each 25 μl PCR mixture contained 2.5μl of 10X PCR buffer, 0.5μl dNTPs 10mM, 2 μl Mgcl2 25 mM, 0.1μl of each primers with 10pmol/ μl concentration,0.3 Unit of Taq DNA polymerase, 14.5μl ddH2O and 5μl (500 ng/ml)of extracted DNA. The amplification process was conducted under following conditions: 95°C for 5 min; then 35 cycles of 94°C for 30s, 60°C for 30s and 72°C for 30s and 72°C for 7 min. Detection of HHV-6 DNA by Real-Time PCR (Syber Green). The detection of HHV-6 DNA was carried out according to Yavarian et al (16) The Plasma and PBMC specimens were tested for HHV-6 DNA. Real-time PCR was done based on SYBR Green/ROX q PCR Master Mix (2X) (Ampliqon, Denmark) kit using ABI system 7300 .The primers were designed for the U22 ORF of both HHV-6 variants (A, B); forward primer: 5´-TCGAAATAAGCATTAATAGGCACACT-3´, reverse primer: 5´-CGGAGTTAA GGCATTGGTTGA -3'which amplified a 98-bp fragment. Thermocycling conditions were as follows, initial heat activation for three minutes at 95°C, followed by 35 cycles of denaturation at 95°C for 15seconds, annealing at 56°C for 30 seconds and final extension step of at 60°C for 30 seconds. Dissociation curve and amplification plot are shown in (fig 1 and  2 ) with positive control and clinical sample.
Detection of Anti-HHV-6 IgG antibody.
Anti-HHV-6 IgG Antibody in the plasma specimens were assayed by ELISA Technique according to manufacturer's instruction (Abnova, Taiwan). Briefly, 100 µl of plasma diluted 1:100 were added to the wells coated with the HHV-6 antigen. Samples were incubated 60 minutes at 37°C and washed 4 times. 100 µL of Px-conjugate was added into each well and incubated 20 minutes at 37°C. After the wells were washed 4 times, 100µL of TMB was added, incubated 20 minutes at room temperature and reaction was stopped and read in an ELISA reader at 630 nm. The presence or absence of anti-HHV-6 IgG was measured in relation to the cut-off calibrator. By dividing the sample or control absorbance by the cut-off calibrator factor an index value <0.9 was calculated to be negative, between 0.9 and 1.1 was equivocal and >1.1 was computed to be positive. Statistical analysis. Clinical and demographic data were entered in SPSS-16 and analyzed. Statistical analysis was assessed by the X 2 test and independent T-Test. P values were determined, and those less than 0.05 were considered to be significant.
Results
Of 59 MS patients, 17 (28%) males and 42 (72%) females, 55 patients suffered from relapsing-remitting MS (RRMS) and four of them had secondary-progressive MS (SPMS). Patients age were ranging from 15 to 55 years (mean±SD, 32±8 years) and in control group it was ranging from 18 to 55 years (mean±SD 33.2 ± 8.2) ( Table 1 ). All of the MS patients were under treatment with different drugs. Most of MS patients (71.1%) were taking Cinovex and rest of them treated with Avonex, Recigen, Betafron, Actafron, Rebif, Zifron and Azaram. 89.83% of MS patients belonged to ethnicity of Fars, 3.38% to Turk, 5.08% to Turkman and 1.06% to Sistani. Detection HHV-6 Genome in plasma and PBMC. Only one (1.7%) of MS patients had shown HHV-6 DNA in its plasma sample. PBMC of all MS patients and plasma and PBMC samples of control group were negative for HHV-6 DNA ( Table 2) . Positive sample belonged to RRMS patient. There was no significant difference between HHV-6 and MS. Detection of IgG Antibody against HHV-6. Anti HHV-6 antibody were demonstrated in 50/59 (84.70%) of MS patients in contrast with 23/28 (82.1%) of healthy controls. All of SPMS patients had anti-HHV-6 IgG antibody of their plasma samples compared to 83.63% of the RRMS patents. The average index antibody for MS patients were 2.94 (Std. Deviation= 2.12) and control group 2.87 (Std. Deviation = 1.83). Normality in these data were analyzed with Kolmogorov-Smirnov test and assumptions of normality didn't reject. According to the independent t test, this Ahmadi A et al difference was not significant and we didn't find significant difference in level of anti-HHV-6 IgG antibody between MS patients and the control group (Table 2) .
Discussion
Family members of the herpesviruses are possible candidates for association with MS disease. Many studies have been conducted on the association between HHV-6 and MS, however, we are faced with controversial results. According to various reports HHV-6 DNA was found in high levels in the CNS,CSF and serum of MS patients instead of many others with no HHV-6 infection in both MS cases and control groups (17) . In the level of active infection our results demonstrated presence of HHV-6 DNA in plasma sample of only one MS patients instead of no HHV-6 infection in peripheral blood mononuclear cells (PBMCs) of MS patients as well as plasma and PBMC of control group. Different studies reported low and high level of HHV-6 DNA presence in MS patients in various areas of Iran and other countries. According to table 3 in recent studies (9, (18) (19) (20) (21) there has been no any report showing results for significant relation between presence of HHV-6 DNA in MS patients and control group. However some of them showed low level of HHV-6 DNA in MS patients as well as detection of viral DNA in both of MS patients and control group. These are in agreement with our finding with low presence of HHV-6 DNA in Blood sample and no association with MS. Instead of these data several studies reported before 2010 (22, 23) showed high frequency of HHV-6 DNA in MS patients and significant relation between MS MS -multiple sclerosis, SD -standard division 
Conclusions
According to the results we concluded that there is no a definite relation in role of Human herpesvirus-6 in etiology of multiple sclerosis. The possible correlation of HHV-6 and MS is still controversial and far from being established.
